Geode Capital Management’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Geode Capital Management’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-837,022	Closed	-$250K	–	4874
2023 Q2	$250K	Sell	837,022 -772,277	-48%	-$233K	﹤0.01%	3943
2023 Q1	$696K	Buy	1,609,299 +39,113	+2%	+$30K	﹤0.01%	3519
2022 Q4	$1.85M	Buy	1,570,186 +343,227	+28%	+$559K	﹤0.01%	3080
2022 Q3	$2.85M	Buy	1,226,959 +538,538	+78%	+$1.41M	﹤0.01%	2959
2022 Q2	$1.52M	Buy	688,421 +111,506	+19%	+$773K	﹤0.01%	3218
2022 Q1	$5.55M	Buy	576,915 +552,323	+2,246%	+$4.95M	﹤0.01%	2735
2021 Q4	$244K	Buy	24,592 +6,071	+33%	+$60.3K	﹤0.01%	4391
2021 Q3	$183K	Hold	18,521	–	–	﹤0.01%	4486
2021 Q2	$181K	Buy	+18,521	New	+$181K	﹤0.01%	4378

Geode Capital Management's GRNA Position: Q3 2023 in Review

Geode Capital Management sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 837,022 shares — an estimated $250K sold.

Geode Capital Management first reported a position in GRNA in Q2 2021 and held it in 9 quarters. The position peaked at $5.55M in Q1 2022. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

Geode Capital Management reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
Geode Capital Management sold 837,022 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $250K.
Geode Capital Management first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q2 2021 and held it in 9 quarters.
Geode Capital Management's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $5.55M in Q1 2022.
0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on Geode Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.